CYP

5.26%

20.0¢ cynata therapeutics limited

Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-21

First 21 Last

Share
Profile

Follow
truss20

852 Posts.

340

12/10/22

14:04

Post #: 64159328
Share

Originally posted by JB1975: ↑

I genuinely welcome your contrarian posts.

When you saw the DSMB announcement and remembers the MEND announcement it was like you were speaking for me and reminding the group. I do think some here misinterpreted the DSMB annoucement relating to MEND as being a sort of endorsement of trial design when it was not.

But DFU in my opinion will he harder to stuff up the trial design for than was MEND.

Yet on the MEND side issue, sepsis, ARDs and CAR-T remain legitimate areas in which good trial designs might test potential therapies that would have merit.

My concern with DFU is not trial design its how much shareholder value has been retained by Ross Macdonald in his capacity as the steward of shareholder value in commercial in confidence arrangements with TekCyte.

With respect to milestones - that get mentioned here - milestones that are not anticipated before being reached are of a different sort than those that are laid out as KPIs ahead of time.

I accept Dr Jolanta Airey's statement that this "is a key milestone, which enables continued enrollment as planned" but it sound's to me like Ross speak.

And Ross's name still appears at the end of the announcement as authorising as CEO and Managing Director and that to me is still bad news for the shares that that is the case.

When Silviu spoke of milestones in the other MSC company you are aware of he used "major milestones" as a sort of way to mitigate failure to completely deliver to expectations set - like that a BLA resubmission would be made by end of the quarter.

In my opinion, CYPs near term share price gains are likely dependent on what MSB does, because CYP isn't hardly doing anything. Unfortunately I don't think MSB is on a positive trajectory either - MSB has just successfully gone dark on delivery dates without being pulled up on it and those delivery dates if they'd been met would have made Ross's planning of GvHD trials easier in my opinion because the FDA responding to MSB would have removed some of the fog.

Yet fog remains.

Expand

Sigh. I guess I have to post this again as it clearly didn't sink in last time. @col69 FYI this is part of the DSMB's responsibilities:

https://www.australianclinicaltrials.gov.au/sites/default/files/content/For%20researchers/Data%20Safety%20Monitoring%20Boards_1.pdf

CYP Price at posting: 36.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

As Nvidia cools, we're looking to Aussie AI

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

There are more pages in this discussion • 28 more messages in this thread...

First 21 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change 0.010(5.26%)		Mkt cap ! $36.13M

Open	High	Low	Value	Volume
20.5¢	20.5¢	20.0¢	$8.749K	42.75K

Buyers (Bids)

No.	Vol.	Price($)
2	19130	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
20.0¢	20000	1

View Market Depth

No.	Vol.	Price($)
2	19130	0.190
1	15000	0.185
1	10000	0.180
1	285	0.175
1	6050	0.165

Price($)	Vol.	No.
0.200	20000	1
0.205	38856	1
0.210	60000	1
0.220	17664	2
0.235	3225	1

Last trade - 13.09pm 06/09/2024 (20 minute delay)

CYP (ASX) Chart

Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-21

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

Shekel Brainweigh investor presentation webinar – the future of retail automation

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

As Nvidia cools, we're looking to Aussie AI

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-21

Top Stories

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

Shekel Brainweigh investor presentation webinar – the future of retail automation

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

As Nvidia cools, we're looking to Aussie AI

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News